Significant step for Salvat laboratories. The Catalan family pharmaceutical company has decided to concentrate its entire production capacity at the factory it has in Alcalá de Henares, in Madrid. The move from the Esplugues de Llobregat plant will be progressive until 2030, according to its new strategic plan approved in July. The company is open to negotiating possibilities of geographical mobility for its staff "responsibly, maintaining dialogue with the legal representatives of the workers during the different phases of the transition".

Jordi Muntañola (Barcelona, 1978) has been the CEO of Salvat laboratories for a year. This molecular biologist from Esteve, who also held positions of responsibility at the Werfen group, has placed Salvat in the club of 100 million in turnover 12 months after initiating a major transformation to enhance the values and characteristics of a family-owned pharmaceutical company with over 70 years of history; a portfolio of its own products, with brands like the antiseptic Cristalmina, and a foundation to which it dedicates a portion of its profits. And, moreover, with great prospects, with the acceleration of the third-party production business and the launch during the first half of this year of a new product in the USA, with the prospect of marketing another next year and another in China. Always accompanied by a local partner, the formula it uses for internationalization, which has led it to be present in more than 60 countries. And without ruling out possible acquisitions, a path that the company may incorporate into the 2027-2030 strategic plan, which it expects to have ready this summer.